Msbio엠에스바이오

Msbio is a recently listed KOSDAQ medical device company trading well below its 52-week high, with little financial detail available in the data.

Msbio listed on KOSDAQ on 2026-10-22 and closed at ₩11,740 on 2026-10-27, for a market cap of about ₩319B. The shares sit roughly 40% below their 52-week high of ₩19,650 and above the 52-week low of ₩9,510. The data contains no annual financials, trailing results, valuation multiples or company profile, so the current state of the business cannot be assessed from this pack.

What stands out

• The price is ₩11,740, about 40% below the 52-week high of ₩19,650 and about 23% above the 52-week low of ₩9,510.
• No annual or trailing financials are in the data, and all valuation multiples (P/E, P/B, P/S, EV/EBITDA) are unavailable.
• Over the 20 trading days shown, institutions net sold about ₩14.6B and foreign investors net sold about ₩5.0B, while retail investors net bought about ₩23.0B.
• Foreign ownership fell from 1.6% to 0.6% over the past 60 days.
• Recent filings include a securities registration statement, a prospectus with amendments, and insider and 5%+ holding reports dated 2026-10-28; no news headlines are listed.

What to watch

• Whether the company publishes its first full financial statements and annual results, since none are in the data yet.
• Details of the securities registration and prospectus amendments, and whether they involve new share issuance that could affect the share count.
• Continued changes in foreign and institutional ownership, and the insider and 5%+ holder reports filed on 2026-10-28.